Shionogi Company Limited

Nagoya University

Yoshinori Yamano

Yasuhiro Nishitani

Yoshito Numata

Takafumi Sato

Toshinaga Tsuji

Osamu Yoshida

Kenji Morimoto

Tsutomu Iwaki

Jun Lu

Yutaka Yoshida

Hirokazu Arimoto

Keiko Kawamoto

Issei Kato

Tatsuro Yasukata

Kayo Yasoshima

Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with. Concretely, the humanized monoclonal antibody of the present invention has an excellent inhibitory activity on the cytotoxicity with respect to a target cell of. Also, the humanized monoclonal antibody of the present invention has a high affinity for PcrV.

Humanized PcrV antibody having anti-pseudomonal activity

Novel glycopeptide antibiotic derivatives. These derivatives are represented by the formula (aglycon part of glycopeptide antibiotic derivative)-(Sac-NH)&#x2014;R[wherein (aglycon part of glycopeptide antibiotic derivative) is the part formed by removing the sugar part from a known glycopeptide antibiotic derivative; (Sac-NH) part is an amino sugar part or a sugar chain part containing an amino sugar; and Rrepresents, e.g., the formula &#x2014;X&#x2014;Ar&#x2014;X&#x2014;Y&#x2014;X&#x2014;Ar(wherein X, X, and Xeach represents 1) a single bond or 2) a heteroatom or heteroatom-containing group selected from the group consisting of &#x2014;N&#x2550;, &#x2550;N&#x2014;, &#x2014;NR&#x2014;, &#x2014;O&#x2014;, etc.; Y represents &#x2014;NRCO&#x2014; or &#x2014;CONR&#x2014; (wherein Rrepresents hydrogen or lower alkyl), etc.)]. These derivatives have antibacterial activity against vancomycin-resistant bacteria.

Glycopeptide antibiotic monomer derivatives

Provided is an effective means for therapy of infection, particularly infection with. Provided are a monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient. Concretely, monoclonal antibody of the present invention has excellent inhibiting activity on cytotoxicity with respect to a target cell of. Also, the monoclonal antibody of the present invention has high affinity with PcrV.

Antibody against PcrV

Cephem compounds having broad antibacterial spectrum

Broad spectrum cephem compounds

Growing community of inventors

Toyonaka, Japan

Yoshinori Yamano